Drug
Kk8123
Kk8123: highest development phase Phase 1/2, developed by Kyowa Kirin. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| KK8123 NCT06525636 | Phase 1/2 | X-linked Hypophosphatemia |
Latest
No recent events.
Follow Kk8123 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.